{
    "relation": [
        [
            "Published Date",
            "Feb 2, 2015",
            "Sep 19, 2014",
            "May 6, 2014",
            "Jan 15, 2014",
            "Jan 13, 2014",
            "Jan 8, 2014",
            "Jun 10, 2013"
        ],
        [
            "Version",
            "9 (current)",
            "8",
            "7",
            "6",
            "5",
            "3",
            "2"
        ],
        [
            "Files",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download"
        ]
    ],
    "pageTitle": "DailyMed - TAFINLAR- dabrafenib mesylate capsule",
    "title": "",
    "url": "http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988860.88/warc/CC-MAIN-20150728002308-00255-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 59710239,
    "recordOffset": 59660019,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{237627=To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch., 5780=Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088., 247664=01/2014, 4057=Revised: January 2014, 234556=Revised: 1/2014, 27319=\u00a92014, GlaxoSmithKline group of companies. All rights reserved.}",
    "textBeforeTable": "Number of versions: 7 TAFINLAR- dabrafenib mesylate capsule View Label Archives for this drug View Label Archives, RxNorm, Get Label RSS Feed More Info on this Drug Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary Related Resources Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk Safety (also available in the left menu) Find additional resources Close All Sections View All Sections Close Labeler -\u00a0GlaxoSmithKline LLC (167380711) 06/10/2013 NDA202806 NDA Marketing End Date Marketing Start Date Application Number or Monograph Citation Marketing Category Marketing Information 10/08/2014 56 in 1 BOTTLE; Type 0: Not a Combination Product NDC:0173-0847-65 3 12/11/2014 06/10/2013",
    "textAfterTable": "RxNorm TAFINLAR- dabrafenib mesylate capsule RxCUI RxNorm NAME RxTTY 1 1424916 dabrafenib 50 MG Oral Capsule PSN 2 1424916 dabrafenib 50 MG Oral Capsule SCD 3 1424916 dabrafenib (as dabrafenib methylsulfate 59.25 MG) 50 MG Oral Capsule SY 4 1424918 dabrafenib 75 MG Oral Capsule PSN 5 1424918 dabrafenib 75 MG Oral Capsule SCD 6 1424918 dabrafenib (as dabrafenib methylsulfate 88.88 MG) 75 MG Oral Capsule SY 7 1425228 Tafinlar 50 MG Oral Capsule PSN 8 1425228 dabrafenib 50 MG Oral Capsule [Tafinlar] SBD 9 1425228 Tafinlar 50 MG (as dabrafenib mesylate 59.25 MG) Oral Capsule SY 10 1425228 Tafinlar 50 MG Oral Capsule SY 11 1425230 Tafinlar 75 MG Oral Capsule PSN 12 1425230 dabrafenib 75 MG Oral Capsule [Tafinlar] SBD 13 1425230 Tafinlar 75 MG (as dabrafenib mesylate 88.88 MG) Oral Capsule SY 14 1425230 Tafinlar 75 MG Oral Capsule SY Get Label RSS Feed for this Drug TAFINLAR- dabrafenib mesylate capsule",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}